MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis

被引：5
|
作者：
Lambros, Laetitia [1 ]
Uguen, Arnaud [1 ,2 ]
机构：
[1] CHRU Brest, Dept Pathol, Brest, France
[2] INSERM, U1053 BaRITOn, Bordeaux, France
来源：
CLINICAL LUNG CANCER | 2019年 / 20卷 / 03期
关键词：
D O I：
10.1016/j.cllc.2018.12.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E418 / E420
页数：3
相关论文
共 50 条
  • [21] MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non -small cell lung cancer?
    Pruis, Melinda A.
    von der Thusen, Jan H.
    Dubbink, Hendrikus Jan
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (22)
  • [22] The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation
    Rocco, Danilo
    Della Gravara, Luigi
    Palazzolo, Giovanni
    Gridelli, Cesare
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (21) : 3043 - 3056
  • [23] Cytomorphology of Non-Small Cell Lung Carcinoma with MET Exon 14 Skipping Mutations
    Labiano, Tania
    Echegoyen, Ana
    Moneo, Marta
    Elizalde, Jesus
    Guerrero, David
    LABORATORY INVESTIGATION, 2024, 104 (03) : S438 - S439
  • [24] MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy
    Wong, Selina K.
    Alex, Deepu
    Bosdet, Ian
    Hughesman, Curtis
    Karsan, Aly
    Yip, Stephen
    Ho, Cheryl
    LUNG CANCER, 2021, 154 : 142 - 145
  • [25] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [26] Immunotherapy for stage IV non-small cell lung cancer patients with MET exon 14 skipping mutation
    Kuon, J.
    Blasi, M.
    Shah, R.
    Christopoulos, P.
    Stenzinger, A.
    Kazdal, D.
    Herth, F. J.
    Heussel, C. P.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 172 - 172
  • [27] Drug Approval: Tepotinib - advanced relapse MET exon-14 in non-small-cell lung cancers
    Poumeaud, Francois
    Girard, Nicolas
    BULLETIN DU CANCER, 2022, 109 (12) : 1228 - 1229
  • [28] An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
    Teng, F.
    Xing, P.
    Hao, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S472 - S472
  • [29] Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
    Wolf, Juergen
    Seto, Takashi
    Han, Ji-Youn
    Reguart, Noemi
    Garon, Edward B.
    Groen, Harry J. M.
    Tan, Daniel S. W.
    Hida, Toyoaki
    de Jonge, Maja
    Orlov, Sergey V.
    Smit, Egbert F.
    Souquet, Pierre-Jean
    Vansteenkiste, Johan
    Hochmair, Maximilian
    Felip, Enriqueta
    Nishio, Makoto
    Thomas, Michael
    Ohashi, Kadoaki
    Toyozawa, Ryo
    Overbeck, Tobias R.
    de Marinis, Filippo
    Kim, Tae-Min
    Laack, Eckart
    Robeva, Anna
    Le Mouhaer, Sylvie
    Waldron-Lynch, Maeve
    Sankaran, Banu
    Balbin, O. Alejandro
    Cui, Xiaoming
    Giovannini, Monica
    Akimov, Mikhail
    Heist, Rebecca S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10): : 944 - 957
  • [30] Analysis of MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.
    Marks, Jennifer Aline
    Yin, Jun
    Halmos, Balazs
    Bazhenova, Lyudmila
    Ramalingam, Suresh S.
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345